Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 16

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 16
---
ed    
 Share(2)   |   |
| Common Stock issuable upon the conversion of shares of Series D Preferred Stock |     |   801,282 |     |    $12.48 |     |            | * |

| * | Represents no potential profit per share or a potential loss per share based on illustrative market price. |

| (1) | Reflects 80% of the conversion price of $15.60 to give effect to the purchase of Series D Preferred Stock at a 20% original issue discount to the stated value thereof. |
| (2) | Based on the closing price of our Common Stock on Nasdaq on August                                                                                                      
 7, 2025 of $8.10 per share.                                                                                                                                             |

The following table includes information relating to the shares of Common Stock registered for resale hereby, including the purchase price each category of Selling Stockholder paid for its securities and the potential profit relating to such securities based upon the registration of 300% of the number of shares into which the Series D Preferred Stock is convertible and conversion at the Floor Price of $3.12.

| Selling Stockholder                                                             |     |  Number of 
    Offered 
     Shares |     | Effective 
  Purchase 
 Price per 
   Offered 
 Share (1) |     |   |  Potential 
 Profit per 
    Offered 
   Share(2) |
|:--------------------------------------------------------------------------------|:----|-----------:|:----|----------:|:----|:--|-----------:|
| Common Stock issuable upon the conversion of shares of Series D Preferred Stock |     | 12,019,231 |     |    $2.496 |     | $ |      5.604 |

| * | Represents no potential profit per share or a potential loss per share based on illustrative market price. |

| (1) | Reflects 80% of the Floor Price of $3.12 to give effect to the purchase of Series D Preferred Stock at a 20% original issue discount to the stated value thereof. |
| (2) | Based on the closing price of our Common Stock on Nasdaq on August                                                                                                
 7, 2025 of $8.10 per share.                                                                                                                                       |

The securities being offered for resale by the Selling Stockholders pursuant to this prospectus represent approximately 81.6% of our total issued and outstanding Common Stock as of August 1, 2025, assuming and after giving effect to the issuance of the maximum